GPC3 and hepatocellular carcinoma: A previous study carried out by Motawi et al. (2019), demonstrated that glypican-3 level is elevated in a large percentage of HCC patients as it promotes metastasis and decreases the apoptosis signaling proteins [22] and so, Shih et al. (2020), proposed that glypican-3 has higher diagnostic accuracy and sensitivity than alpha-fetoprotein in the initial diagnosis of HCC and it is an important marker to differentiate between benign liver diseases and the malignant HCC cases [40].